JACKSON CENTER, PA / ACCESSWIRE / September 27, 2022 / Halberd Corporation (OTC PINK:HALB) entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a ...

Halberd demonstrated elimination of the final two of the "Top Ten" antigens linked to neurodegenerative diseases. Halberd demonstrated that its antigen elimination process is able to selectively ...

Halberd Corporation is actively seeking research partners and investors focused on objective, longitudinal behavioral biomarkers across anxiety, PTSD, Traumatic Brain Injury (TBI), and related ...

Mississippi State University (MSU) is well on their way in testing Halberd's patent-pending nasal spray to mitigate the neurological effects resulting from traumatic brain injuries (TBI). By directly ...

A Major Step Towards the Elimination of Multiple Infectious Diseases and Possible Treatment for Alzheimer's Disease/PTSD/CTE Felder continued, "Our method envisions utilizing a dialysis variation in ...

JACKSON CENTER, PA / ACCESSWIRE / October 18, 2022 / Halberd Corporation (OTC PINK:HALB) has successfully eliminated various antibiotic resistant bacteria from buffer solution in-vitro through the use ...

JACKSON CENTER, PA / ACCESSWIRE / February 6, 2024 / Halberd Corporation's (OTC PINK:HALB) and Athena GTX's executives interviewed on "The Street Reports," discuss the relationship between Halberd and ...